^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Testicular Cancer |
| Drug: | Libtayo (cemiplimab-rwlc) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
…the panel considers pembrolizumab immunotherapy to be useful in certain circumstances (ie, in patients with MSI-high/deficient MMR [MSI-H/dMMR] or tumor mutation burden-high [TMB-H] tumors).
